Skip to content

Industry News

Ardian-backed Laboratoires Anios Buys Majority Stake in Endoclear

2 July 2015

(PEHub) Laboratoires Anios, which is backed by Ardian, has acquired a majority stake in Endoclear. No financial terms were disclosed. Based in Brazil, Endoclear is a provider of automatic endoscope processing systems.


July 2, 2015. Laboratoires Anios – a European leader in the disinfection of hospital and clinical environments and a reference player for industry and communities linked to accommodation and catering announces the acquisition of an 80% stake in Endoclear, the Brazilian leader in automatic endoscope disinfection processes. It is their third acquisition, and the second overseas, following the takeover of the family company in December 2013 by Bertrand Letartre, Thierry Letartre and Ardian, the independent private investment company.

Based in Cristais Paulistas in the São Paulo state (Brazil) and founded by Carlos Henrique in 1985, Endoclear is a company specialising in the design, development and production of equipment for the automatic endoscope reprocessing. It provides hospitals with an automatic high-level disinfection system for their flexible endoscopes.

Further to the acquisition of Soluscope in April 2014, joining forces with Endoclear will allow Laboratoires Anios to expand their offer of automatic systems for reprocessing endoscopes to Brazil by proposing a complementary offer of chemicals and equipment. Brazil represents a market of 4,800 private hospitals and 2,000 public hospitals. The health sector is expanding fast into cutting-hedge technologies, is switching from manual into automatic disinfection, and such acquisition will give Laboratoires Anios the opportunity to strengthen position into a market with strong long-term growth potential.

For Laboratoires Anios, taking a majority holding in Endoclear will facilitate combining of knowledge and expertise. Both companies will profit from complementary input: Endoclear will benefit from leading edge innovation and the highest quality standards of Soluscope, while Soluscope will benefit from Endoclear’s expertise in the field, its market-leading position and access to a wide installed base (Endoclear has close to 50% market share in Brazil).

Laboratoires Anios confirm their target to increase international turnover to reach 50% by 2020, positioning the group among world leaders in the hospitals disinfection market.


N°1 in France and European leader on the disinfection market.

Laboratoires Anios have been producing disinfection products since 1898. A major player in hygiene in hospitals, clinics and medical professions, also present in the cosmetics, pharmaceutical and agrifood industries, or with local authorities linked to accommodation or catering, in France and more than 80 other countries. With 700 employees, 2 production sites and their 1000m² Research Centre in Northern France, 1 production site in the South of France, one in Italy, one in Turkey and one in Argentina, Laboratoires Anios manufactures 120 000 bottles per day and numbers 12 000 professional customers.